A headline says AI discovered a new drug. What has to happen before that discovery helps a patient?

Jivesh Sharma, M.D., examines ProteinTalks, a September 2026 Nature study of breast cancer cells' responses to drugs, and the published 2025 Phase 2a rentosertib trial in idiopathic pulmonary fibrosis. Laboratory and retrospective results do not prove that model-guided treatment improves survival. Commercial ties are disclosed.

Release-day update, October 6, 2026: Insilico Medicine announced on September 10 that the first patient was dosed in the GENESIS-IPF-3 Phase 3 trial. Starting a trial does not establish benefit. Rentosertib remains investigational. The narration examines the 2025 Phase 2a results. https://insilico.com/news/isn1009261-insilico-medicine-doses-first-patient-genesis-ipf-3

Research cutoff: October 5, 2026; source status rechecked October 6.

Thank you for listening and watching. Follow HealthIT.com and suggest a topic: https://www.healthit.com/feedback

Talia is an AI cohost. Jivesh's narration uses an authorized AI-generated version of his voice. General education, not personal medical advice. HealthIT.com is part of Jivesh's healthcare technology work and the Nexgen Precision portfolio.

Primary sources:

FDA drug-development process: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process

Sun et al. Nature, September 9, 2026: https://www.nature.com/articles/s41586-026-11001-9

Westlake University: https://en.westlake.edu.cn/news_events/westlakenews/research/202609/t20260918_69874.html

Xu et al. Nature Medicine, 2025: https://www.nature.com/articles/s41591-025-03743-2

FDA January 2025 draft guidance concerns AI supporting regulatory decisions, rather than drug discovery itself: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological

00:00 The question behind the headline

00:46 A candidate still has to earn its place

01:59 September: a model of drug response

03:21 Early trials are not the finish line

05:12 What would count as useful progress?

06:21 Thank you and next conversation